Literature DB >> 1724909

The effects of milrinone in the neonatal pig heart.

N T Ross-Ascuitto1, R J Ascuitto, D Ramage, K H McDonough.   

Abstract

Milrinone, a selective inhibitor of phosphodiesterase (PDE), was examined in neonatal hearts and in ventricular myocytes. Isolated, paced (180 beats/min), isovolumically beating hearts from pigs, less than 3 days of age, were perfused with an erythrocyte-enriched solution. In one group (control, n = 6), milrinone was studied at perfusate concentrations of 1, 10, and 100 micrograms/ml. In a second group (postischemia, n = 10), hearts were subjected to 30 minutes of no-flow ischemic arrest, prior to the addition of milrinone. Left ventricular peak systolic pressure (PSP) and end-diastolic pressure, coronary flow (CF), heart rate (HR), and myocardial oxygen consumption (MVO2) were measured. The PSP averaged approximately 100 mmHg during the baseline periods for both groups and decreased to approximately 85 mmHg in those hearts subjected to ischemic arrest. In both groups, PSP increased approximately 14% at the 1 micrograms/ml concentration of milrinone. No additional increases in PSP were observed in the control group at the higher concentrations. However, PSP increased 28% and 41% (p less than 0.05), in the postischemia group at the 10 and 100 micrograms/ml concentrations, respectively. The CF averaged approximately 3 ml/min/g during the baseline periods of both groups and increased significantly at each milrinone concentration. The HR in both groups increased to approximately 200 and approximately 250 beats/min at the 10 and 100 micrograms/ml concentrations, respectively. Additionally, milrinone's effects in intact hearts were found to be comparable to those of isobutylmethyl xanthine (IBMX), a nonspecific PDE inhibitor. In isolated myocytes, however, milrinone produced only modest increases in cAMP levels, compared to IBMX.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1724909     DOI: 10.1007/bf00143529

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  26 in total

1.  The inotropic effects of amrinone and milrinone on neonatal and young canine cardiac muscle.

Authors:  O Binah; B Sodowick; Y Vulliemoz; P Danilo; M Rosen
Journal:  Circulation       Date:  1986-03       Impact factor: 29.690

2.  Ventricular function and fatty acid metabolism in neonatal piglet heart.

Authors:  R J Ascuitto; N T Ross-Ascuitto; V Chen; S E Downing
Journal:  Am J Physiol       Date:  1989-01

3.  Effect of milrinone on myocardial mechanical function and cyclic AMP content in the fetal rabbit.

Authors:  S Ogawa; T Nakanishi; K Kamata; A Takao
Journal:  Pediatr Res       Date:  1987-09       Impact factor: 3.756

Review 4.  Milrinone. A preliminary review of its pharmacological properties and therapeutic use.

Authors:  R A Young; A Ward
Journal:  Drugs       Date:  1988-08       Impact factor: 9.546

Review 5.  Positive inotropic/vasodilator agents.

Authors:  W S Colucci
Journal:  Cardiol Clin       Date:  1989-02       Impact factor: 2.213

Review 6.  Studies on the mechanism of action of the bipyridine milrinone on the heart.

Authors:  A E Farah; C J Frangakis
Journal:  Basic Res Cardiol       Date:  1989       Impact factor: 17.165

7.  Metabolic responses to varying restrictions of coronary blood flow in swine.

Authors:  A J Liedtke; H C Hughes; J R Neely
Journal:  Am J Physiol       Date:  1975-02

8.  Relative vulnerability of neonatal and adult hearts to ischemic injury.

Authors:  C Wittnich; C Peniston; D Ianuzzo; J G Abel; T A Salerno
Journal:  Circulation       Date:  1987-11       Impact factor: 29.690

9.  Cardioplegic protection of the child's heart.

Authors:  C Bull; J Cooper; J Stark
Journal:  J Thorac Cardiovasc Surg       Date:  1984-08       Impact factor: 5.209

Review 10.  Overview of cardiovascular physiologic and pharmacologic aspects of selective phosphodiesterase peak III inhibitors.

Authors:  D B Evans
Journal:  Am J Cardiol       Date:  1989-01-03       Impact factor: 2.778

View more
  1 in total

1.  Milrinone is preferred to levosimendan for mesenteric perfusion in hypoxia-reoxygenated newborn piglets treated with dopamine.

Authors:  Namdar Manouchehri; David L Bigam; Thomas Churchill; Chloe Joynt; Maximo Vento; Po-Yin Cheung
Journal:  Pediatr Res       Date:  2012-01-11       Impact factor: 3.756

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.